As an annual event dedicated to pharmaceutical intellectual property, 4th China Pharma IP Summit 2019 (CPIPS2019) was successfully held at Primus Hotel Shanghai Hongqiao China on 23rd -25th , Oct with a record-breaking over 540 attendees from global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers, and over 56 speakers given presentation. CPIPS 2019, themed as “Pharma IP Challenges and Opportunities for Global Pharma Innovation” topics covered the global IP Landscape and hot issues in patent prosecution, patent examination rules and comparison in different jurisdictions include mainly China, Europe, US, Japan, South Korea,India and Brazil. And compare to past three years, CPIPS 2019 given half day discussion on patent prosecution of Traditional Chinese Medicine and Challenges of Going Out“

This year's distinguished speaker gathers not only officials from Natinal IP Offices, well-known IP experts and law firms, but also IP executives and researchers of leading Pharma companies from both Generic and Innovators, including Reexamination and Invalidation Department of the Patent Office,Jones Day,Beijing Intellectual Property Institute,BeiGene, CHIA TAI TIANQING,Luye Pharma Group,AstraZeneca,Beijing Intellectual Property Court,King & Wood Mallesons, Perkins Coie LLP,3SBio Group,Sunovion Pharmaceutical,Sun Pharmaceutical,Boehmert & Boehmert,Sanofi, Junshi Biosciences,UCB Biopharma,Shanghai Henlius Biotech,Sandoz,Japan Patent Office,Dr. Reddy's Laboratories, Dannemann Siemsen,Bayer Group,Tasly Holding Group, China Shineway Pharmaceutical Group,YILING PHARMACEUTICAL,Yabao Pharmaceutical and etc., Were all involved in very constructive and productive discussions over the balance between patent protection and public health, domestic and international patent rules, litigation, invalidation, challenges and the future trends from a variety of perspectives.

General Overview of CPIPS 2019

CPIPS 2019 : IP Challenges & Opportunities for Global Pharma Innovation
Oct 23rd:	Focus on China: IP Reform in China (Patent Linkage,Regulatory Data Protection,Patent Term Restoration),Patent Examination Practices (Data Supplementation, Compound Inventions,Biological Sequences) and Challenges ,Opportunities for Generic and Innovators under New Environment in China
Oct 24th AM:	Focus On US: Patent Layout, Inter Party Review, Generic Drug Launches, Biosimilar Patent Litigation and IP Strategy in US
Oct 24th PM:	Focus on Europe: Updates and Implication of Brexit, Unitary Patent & UPC and Patent Landscape of Global Antibodies
Oct 25th AM:	Focus on Japan, India, South Korea and Brazil: IP System, Patent Examination Practices, Case Studies of India Generic Company
Oct 25th PM:	Focus on Traditional Chinese Medicine: Patenting Situation & Creative Evaluation for TCM, IP Challenges and Opportunities of Going out

Pictures from CPIPS 2019

CPIPS 2019 Partners

About CPIPS:

China Pharma IP Summit is an annual event aimed to Promote intellectual property protection and pharmaceutical innovation which was initialed by Shanghai YIP Events science 2016, and supported by Pharma IP Right Research Committee of Chinese Pharmaceutical Association. CPIPS has been held four times, with the number of participants increasing from 170+ in 2016 to 550+ in 2019.It has become the most influential event in Pharma IP filed in China.